This webinar will review both broad concepts and key details of genes associated with hereditary risk of breast, ovary, prostate, and pancreas cancer. Familiarity with genes beyond BRCA1 and BRCA2 is important for comprehensive cancer genetic testing and can inform recommendations for cancer screening, risk-reduction, and treatment. These genes include ATM, BARD1, BRIP1, CHEK2, PALB2, RAD51C, and RAD51D. The cancer risks associated with inherited pathogenic variants (PVs) in these genes vary, introducing important nuances into risk assessment and counseling regarding medical interventions.
Level of instruction: intermediate
Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.
Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.